Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma by Yifei Cheng, Xiaofang Chen, Li Feng, Zhicheng Yang, Liyun Xiao, Bin Xiang, Xiaodong Wang, Dongbin Liu, Penghui Lin, Jieyi Shi, Guohe Song, Wulei Qian, Boan Zhang, Yanan Xu, Zheng Gao, Lv Chen, Yingcheng Wu, Jiaqiang Ma, Youpei Lin, Haichao Zhao, Lihua Peng, Xuebin Mao, Yang Liu, Hao Hou, Mingyu Yang, Yuan Ji, Xiaoying Wang, Jian Zhou, Xun Xu, Xiyang Liu, Wu Wei, Xiaoming Zhang, Qiang Gao, Hu Zhou, Yidi Sun, Kui Wu, Jia Fan

Get full text

2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignan... by Michael Sandherr, Jannik Stemler, Enrico Schalk, Tessa Hattenhauer, Marcus Hentrich, Bernd Hertenstein, Christian Hohmann, Sibylle C. Mellinghoff, Rebekka Mispelbaum, Christina Rieger, Martin Schmidt-Hieber, Rosanne Sprute, Guenter Weiss, Oliver A. Cornely, Larissa Henze, Cornelia Lass-Floerl, Gernot Beutel, Annika Y. Classen, Noemi F. Freise, Meinolf Karthaus, Philipp Koehler, Robert Krause, Julia Neuhann, Hans Martin Orth, Olaf Penack, Markus Schaich, Karsten Spiekermann, Sebastian Voigt, Florian Weissinger, Elena Busch

Get full text

The TB27 Transcriptomic Model for Predicting Mycobacterium tuberculosis Culture Conversion by Maja Reimann, Korkut Avsar, Andrew DiNardo, Torsten Goldmann, Gunar Günther, Michael Hoelscher, Elmira Ibraim, Barbara Kalsdorf, Stefan Kaufmann, Niklas Köhler, Anna Mandalakas, Florian Maurer, Marius Müller, Dörte Nitschkowski, Ioana Olaru, Cristina Popa, Andrea Rachow, Thierry Rolling, Helmut Salzer, Patricia Sanchez-Carballo, Maren Schuhmann, Dagmar Schaub, Victor Spinu, Elena Terhalle, Markus Unnewehr, Nika Zielinski, Jan Heyckendorf, Christoph Lange

Get full text

Evaluating Adherence to Antiretroviral Therapy Using Pharmacy Refill Records in a Rural Treatment Site in South Africa by George Gachara, Lufuno G. Mavhandu, Elizabeth T. Rogawski, Cecile Manhaeve, Pascal O. Bessong

“…Logistic regression was also performed to determine the relationship between adherence and virologic suppression and the adherence threshold resulting in <10% virologic failure. …”
Get full text

Long-Term Outcome of an HIV-Treatment Programme in Rural Africa: Viral Suppression despite Early Mortality by Roos E. Barth, Hugo A. Tempelman, Robert Moraba, Andy I. M. Hoepelman

“…To define the long-term (2–4 years) clinical and virological outcome of an antiretroviral treatment (ART) programme in rural South Africa. …”
Get full text

Comparison of Expectant and Excisional/Ablative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in the Era of HPV Testing by Kevin Dominique Tjandraprawira, Adeola Olaitan, Aviva Petrie, Nafisa Wilkinson, Adam N. Rosenthal

“…Among 175 (52.9%) patients initially managed conservatively, 77.3% (133/172) regressed, 13.4% (23/172) persisted, 9.3% (16/172) progressed to CIN3+, and 97 (56.4%) patients achieved virological regression. 156 (47.1%) patients underwent initial excision/ablation, with an 89.4% (110/123) virological cure rate. …”
Get full text

Restoration of Innate and Adaptive Immune Responses by HCV Viral Inhibition with an Induction Approach Using Natural Interferon-Beta in Chronic Hepatitis C by Y. Kishida, N. Imaizumi, H. Tanimura, Y. Haruna, S. Kashiwamura, T. Kashiwagi

“…IL-15 was increased at the end of induction therapy in both early virologic responders (EAVRs) and late virologic responders (LAVRs); CXCL-8, CXCL-10, and CCL-4 levels were significantly decreased (𝑃<0.05) in EAVR but not in LAVR during NCT, and IL-12 increased significantly (𝑃<0.05) and CXCL-8 decreased significantly (𝑃<0.05) after the end of NCT in EAVR but not in LAVR. …”
Get full text

Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients by James M. Mikula, Chiu-Bin Hsiao, Joshua R. Sawyer, Qing Ma, Gene D. Morse

“…The primary outcome of virologic suppression was defined as <50 copies/mL at 24 weeks. …”
Get full text

Ocular manifestations and treatment safety in hepatitis C patients undergoing direct-acting antiviral therapy: a prospective cohort study by Guilherme Thomé de Carvalho, Carlos Eduardo Brandão Mello, Kelma Macedo Pohlmann Simões, Mário Martins dos Santos Motta, Max Kopti Fakoury, Bruno Vasconcelos Coimbra, Laura Gomes Nunes Melo, Flávio Mac Cord Medina

“…All patients achieved sustained virological response, and a notable improvement in fibrosis degree post-treatment was observed. …”
Get full text

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy by Dorota Zarębska-Michaluk, Iwona Buczyńska, Krzysztof Simon, Magdalena Tudrujek-Zdunek, Ewa Janczewska, Dorota Dybowska, Marek Sitko, Beata Dobracka, Jerzy Jaroszewicz, Paweł Pabjan, Jakub Klapaczyński, Łukasz Laurans, Włodzimierz Mazur, Łukasz Socha, Olga Tronina, Miłosz Parczewski, Robert Flisiak

“…Overall sustained virologic response (SVR) rate was 81% and 86% in intent-to-treat (ITT) and modified ITT analysis, respectively (74% and 78% in virologic failures, 92% and 100% in nonvirologic failures). …”
Get full text

The Clinical Cost of Delays in Switching Therapy by Sharon Walmsley

“…New guidelines suggest that the goal of therapy should be maximal virological suppression. This is best achieved by using combinations of agents to which the virus is most likely to have some susceptibility and, where possible, by using agents within a new therapeutic class. …”
Get full text

Treatment of Chronic Hepatitis C Infection among Current And Former Injection Drug Users within a Multidisciplinary Treatment Model at a Community Health Centre by Adam I Newman, Shelley Beckstead, David Beking, Susan Finch, Tina Knorr, Carol Lynch, Meredith MacKenzie, Daphne Mayer, Brenda Melles, Ron Shore

“…Of the 14 patients who initiated antiviral treatment in the study period, eight (57%) achieved sustained virological response. Regardless of virological outcome, patients who initiated treatment showed positive trends toward increased social and psychiatric stability, and decreases in high-risk behaviours. …”
Get full text

Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study by D. T. Abrurakhmanov, V. G. Morozov, I. G. Nikitin, P. O. Bogomolov, N. I. Geyvandova, Ye. N. Bessonova, I. G. Bakulin, V. A. Isakov, K. V. Zhdanov, M. V. Mayevskaya, Ye. A. Nurmukhametova, E. Z. Burnevich, Ye. V. Chesnokov, V. D. Pasechnikov, A. Hill, I. Lonjon-Domanec, S. N. Kizhlo

“…Sustained virologic response was achieved in 73 (80%) of patients available for analysis (n=91). …”
Get full text

Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients by Long-Shan Ji, Qiu-Tian Gao, Ruo-Wen Guo, Xin Zhang, Zhen-Hua Zhou, Zhuo Yu, Xiao-Jun Zhu, Ya-Ting Gao, Xue-Hua Sun, Yue-Qiu Gao, Man Li

“…To compare the clinical efficacy of the combination therapy with Bushen formula (BSF) plus entecavir (ETV) in naïve chronic hepatitis B (CHB) patients and that in CHB patients with partial virological response to ETV and explore the relevant immunoregulatory mechanism. …”
Get full text

Time to First-Line Antiretroviral Treatment Failure and Its Predictors among HIV-Positive Children in Shashemene Town Health Facilities, Oromia Region, Ethiopia, 2019 by Endale Zenebe, Assefa Washo, Abreham Addis Gesese

“…In resource-limited settings, treatment failure is often diagnosed based on the clinical or immunological criteria which occur way after the occurrence of virological failure. Previous limited studies have evaluated immunological and clinical failure without considering virological failure in Ethiopia. …”
Get full text

Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis C by N. B. Kovaleva

“…At AVT, including Altevir® and ribavirin to CHC patients with 1b genotype of HCV and favorable prognosis of virologic response, 66% SVR rate can be achieved.…”
Get full text

Hyperferritinemia at the patient with chronic hepatitis C by Ye. N. German, A. O. Buyeverov, M. V. Mayevskaya, Ch. S. Pavlov, V. T. Ivashkin, A. A. Levina

“…After cessation of the treatment course clinical and laboratory abnormalities reduced. Sustained virologic response was ascertained.…”
Get full text

Viral Response to Specifically Targeted Antiviral Therapy for Hepatitis C and the Implications for Treatment Success by Curtis L Cooper

“…Collectively, specifically targeted antiviral therapy for HCV (STAT-C) molecules achieve rapid viral suppression and very high rapid virological response rates, and improve sustained virological response rates. …”
Get full text

STORAGE OF PIGLET KIDNEYS AT SUBNORMAL TEMPERATURES FOR PRIMARY TRYPSINIZED CELL MONOLAYER PREPARATION by B. L. Manin, N. V. Koropova, V. A. Starikov, I. V. Vologina

“…Optimization of the technology for preparation of the primary cells suitable for virological studies requires long-term storage of internal organs and tissues. …”
Get full text

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study by Hernando Knobel, Esperanza Cañas-Ruano, Ana Guelar, Pablo Knobel, Judit Villar-García, Alicia González-Mena, Ceclia Canepa, Itziar Arrieta-Aldea, Augustin Marcos, Agustí Abalat-Torrres, Roberto Güerri-Fernández

“…The primary objective was to evaluate treatment discontinuation rates; safety and virologic outcomes were also evaluated. Results 690 PLWH were included, 358 in the D/L and 332 in the B/F/T, and a median follow-up of 728 and 1013 days, respectively. …”
Get full text